Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/07/23
Strength Seen in Arvinas, Inc. (ARVN): Can Its 6.3% Jump Turn into More Strength?Zacks Investment Research • 10/31/23
Potential of Arvinas' PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPCGlobeNewsWire • 10/22/23
Arvinas Gives Back to Local Greater New Haven Community in Second Annual Impact DayGlobeNewsWire • 10/18/23
Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023GlobeNewsWire • 10/15/23
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023GlobeNewsWire • 10/15/23
Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/08/23
Arvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC® ER degrader being developed in ER+/HER2- Breast CancerGlobeNewsWire • 07/31/23
Arvinas, Inc. (ARVN) Moves 17.5% Higher: Will This Strength Last?Zacks Investment Research • 06/13/23
Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H MutationsGlobeNewsWire • 06/08/23
Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual CongressGlobeNewsWire • 05/08/23
Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/05/23
Arvinas to Present at the Bank of America Securities 2023 Healthcare ConferenceGlobeNewsWire • 05/03/23
Arvinas and Quantum Leap Healthcare Announce Clinical Study to Evaluate Vepdegestrant (ARV-471) in I-SPY-2 Endocrine Optimization Platform (EOP) Clinical TrialPRNewsWire • 05/02/23
Arvinas, Inc. (ARVN) Surges 7.6%: Is This an Indication of Further Gains?Zacks Investment Research • 04/14/23
Arvinas Appoints Kelly Page as Senior Vice President, Global Head of Oncology Strategy and Program LeadershipGlobeNewsWire • 04/03/23
Arvinas: PROTAC Platform Shows Promise In Clinical Trials For Oncology IndicationsSeeking Alpha • 03/29/23
Arvinas Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateGlobeNewsWire • 02/23/23
Arvinas, Inc. (ARVN) Soars 10.3%: Is Further Upside Left in the Stock?Zacks Investment Research • 01/11/23